Mumbai-based Ipca Laboratories has received approval for its Anti-malarial (finished fixed dose) combination formulation - Artemether and Lumefantrine under World Health Organisation's pre-qualification programme.
In a statement to the Bombay Stock Exchange, the company said that this makes lpca Labs the fourth company in the world to have pre-qualification for this product.
The list of pre-qualified medicinal products is used principally by United Nations agencies including UNAIDS and UNICEF- to guide their procurement decisions.
The pre-qualification programme was created by WHO in 2001 to increase access to priority medicinal products that meet unified standards of acceptable quality, safely and efficacy, currently focusing on those medicines used for treatment of diseases such as malaria.
The company's scrip was trading at Rs 993, up 2.07 per cent on the BSE.
